NUVB

Nuvation Bio Inc

Add to Watchlist

Advanced Chart

2.460

-0.09(-3.529%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.580

Open

2.550

VWAP

Vol

4.49M

Mkt Cap

839.51M

Low

2.425

Amount

EV/EBITDA(TTM)

Total Shares

248.17M

383.52M

EV/OCF(TTM)

P/S(TTM)

Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

3.62M

+398.39%

416.67K

-70.96%

Estimates Revision

The market is revising Upward the revenue expectations for Nuvation Bio Inc. (NUVB) for FY2025, with the revenue forecasts being adjusted by 8.17% over the past three months. During the same period, the stock price has changed by 9.33%.

Revenue Estimates for FY2025

Revise Upward

+8.17%

In Past 3 Month

Stock Price

Go Up

+9.33%

In Past 3 Month

6 Analyst Rating

200.81% Upside

Wall Street analysts forecast NUVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVB is 7.40 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

200.81% Upside

Current: 2.460

Low

5.00

Averages

7.40

High

10.00

200.81% Upside

Current: 2.460

Low

5.00

Averages

7.40

High

10.00

RBC Capital

Outperform

NULL

downgrade

$10 -> $6

2025-06-18

Reason

RBC Capital

Price Target

$10 -> $6

2025-06-18

downgrade

Outperform

NULL

Reason

RBC Capital lowered the firm's price target on Nuvation Bio to $6 from $10 but keeps an Outperform rating on the shares. The firm is updating its model following the company's recent approval of Ibtrozi and transformation into a commercial stage biotech, the analyst tells investors in a research note. RBC adds that it sees some potential challenges for Ibtrozi's launch such as patient finding and near-term competitive headwinds, but also believes that these are outweighed by the drug's favorable profile, long treatment duration, and improving dx rates. The firm further notes that the stock is steeply discounting the newly realized commercial opportunity.

JonesResearch

Soumit Roy

Buy

maintain

$10

2025-06-11

Reason

JonesResearch

Soumit Roy

Price Target

$10

2025-06-11

maintain

Buy

Reason

JonesResearch analyst Soumit Roy keeps a Buy rating on Nuvation Bio with a $10 price target after the FDA approved Ibtrozi for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The firm's physician call yesterday indicated "clear market potential" for Ibtroz. The physician did not bring up any of the adverse events as a concern, but thinks the drug will have a measured ramp of adoption due to rare disease type prevalence and less frequent decision making points, the analyst tells investors in a research note. Jones believes the warnings and precautions on the label are as expected for Ibtrozi, is inline with the class drug, and is better than peer drugs, such as Augtyro, Xalkori and Rozlytrek. Xalkori has added warnings for severe visual loss and cardia and Rozlytrek has added warnings for congestive heart failure, the firm adds.

JMP Securities

Silvan Tuerkcan

Buy

Initiates

2025-04-23

Reason

JMP Securities

Silvan Tuerkcan

Price Target

2025-04-23

Initiates

Buy

Reason

Citizens JMP analyst Silvan Tuerkcan initiated coverage of Nuvation Bio with an Outperform rating and $6 price target. Nuvation is a clinical-stage biotechnology company focused on developing novel targeted therapies for various cancer types, the analyst tells investors in a research note. The firm says that in the current climate, it favors commercial or near-commercial companies that have potential for rapid sales growth. It views Nuvation's taletrectinib as the best-in-class potential ROS1 TKI for the treatment of ROS1-positive, non-small cell lung cancer.

Jones Trading

Soumit Roy

Strong Buy

Initiates

$10

2025-03-12

Reason

Jones Trading

Soumit Roy

Price Target

$10

2025-03-12

Initiates

Strong Buy

Reason

JonesResearch analyst Danya Ben-Hail initiated coverage of Nuvation Bio with a Buy rating and $10 price target. The company is focused on developing clinical stage targeted therapeutics with best in class durability and prolonged survival in lung cancer and glioma and also has an experienced management team headed by its founding CEO, Dr. David Hung, who sold Medivation to Pfizer for $14B in 2016, the analyst tells investors in a research note. JonesResearch adds it is focusing on the company's two programs that Nuvation Bio acquired from AnHeart Therapeutics in April 2024 - ROS1 inhibitor taletrectinib and IDH1 inhibitor safusidenib - with key updates expected from both assets in 2025.

HC Wainwright & Co.

Robert Burns

Strong Buy

Maintains

$11 → $10

2025-03-10

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$11 → $10

2025-03-10

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Maintains

$10 → $11

2025-01-23

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$10 → $11

2025-01-23

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Nuvation Bio Inc (NUVB.N) is -3.70, compared to its 5-year average forward P/E of -11.13. For a more detailed relative valuation and DCF analysis to assess Nuvation Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.13

Current PE

-3.70

Overvalued PE

0.94

Undervalued PE

-23.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

45.44

Current PS

28.24

Overvalued PS

231.77

Undervalued PS

-140.90